| Form | Liquid |
|---|
| Host Species | Humanized |
|---|
| Clonality | Monoclonal |
|---|
| Isotype | IgG1-kappa |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin Level | Please contact the lab for this information. |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Species Reactivity | Human |
|---|
| Target | SLAMF7, CRACC, Protein 19A, SLAM family member 7, CD2-like receptor-activating cytotoxic cells, Membrane protein FOAP-12, CD319, Novel Ly9, CD2 subset 1, CS1 |
|---|
| Storage Buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Expression System | Mammalian Cells |
|---|
| Accession Number | Q9NQ25 |
|---|
| Background | Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents.<br>• SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin., PMID:28424516<br/>• 2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer., PMID:30347240<br/>• CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma., PMID:23731618<br/>• CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes., PMID:17878365<br/>• The multifaceted role of CS1 (SLAMF7) in immunoregulation: Implications for cancer therapy and autoimmune disorders., PMID:40073958<br/>• Hematologic Malignancies: Plasma Cell Disorders., PMID:28561703<br/>• Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma., PMID:28356715<br/>• 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes., PMID:11513145<br/>• Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma., PMID:39060023<br/>• Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma., PMID:27533882<br/> |
|---|
| Alternative Names | ABBV-383, PR-1471272, ABBV-838, 1826819-57-1 |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|